Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.
Sign Up to like & getrecommendations! Published in 2019 at "Immunity"
DOI: 10.1016/j.immuni.2019.04.010
Abstract: Despite compelling rates of durable clinical responses to programmed cell death-1 (PD-1) blockade, advances are needed to extend these benefits to resistant tumors. We found that tumor-bearing mice deficient in the chemokine receptor CXCR3 responded… read more here.
Keywords: cxcr3 chemokine; cell; chemokine system; chemokine ... See more keywords